Kincell Bio and Cellipont Bioservices have completed their merger to form Kincellis Advanced Therapies, bringing together complementary cell therapy platforms, 140,000 square feet of manufacturing space and more than 250 employees across three U.S. sites.
Thursday, September 17, 2026
While gene therapies have demonstrated transformative clinical benefit, their adoption remains limited by manufacturing challenges and cost.
Wednesday, September 16, 2026
Cell expansion has evolved from a necessary manufacturing step into one of the defining challenges of modern cell therapy, sitting at the intersection of biology, engineering, manufacturing and quality. As the field expands into new indications and larger patient populations, overcoming this ...
Wednesday, September 09, 2026
As the next generation of RNA therapeutics takes the CGT stage, the technology is moving beyond its COVID-era breakout role. It could enable new approaches to in vivo CAR-T, address diseases beyond the reach of conventional gene replacement and editing technologies, and expand the therapeutic ...
Tuesday, September 01, 2026
For many CGT companies, the U.S. has long been the default starting point for new ventures. In recent years, that model appears to be weakening, as more companies look beyond the U.S. earlier in their development.
Wednesday, August 26, 2026
RNA’s reputation may have been forged by a pandemic, but its future will likely be determined by something far less dramatic: the steady accumulation of clinical data, regulatory milestones and, ultimately, patient benefit
Wednesday, August 19, 2026
Developers who build regulatory strategy into their manufacturing planning from the outset and design to the highest applicable cross-regional standard, will be better positioned to navigate complexity and deliver therapies to patients.
We invited cell and gene therapy CDMOs to discuss the most common pressure points in sponsor relationships.
In this roundtable series, CDMOs describe what works — and what doesn’t — in sponsor relationships
We invited cell and gene therapy CDMOs to discuss the most common pressure points in sponsor relationships.